Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2020 Financials and to Provide an Update on Development Programs on March 1, 2021
February 22, 2021 06:45 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will...
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Offering
December 04, 2020 12:54 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its...
Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Offering
December 01, 2020 21:48 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has priced...
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
December 01, 2020 16:03 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the launch of a...
Reata Provides Update on Omaveloxolone Program for Patients with Friedreich’s Ataxia
November 24, 2020 17:00 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that the...
Reata Announces Positive Results From Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome
November 09, 2020 06:45 ET
|
Reata Pharmaceuticals, Inc.
BARDOXOLONE ACHIEVED THE YEAR 2 PRIMARY AND KEY SECONDARY ENDPOINTS WITH STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EGFR AS COMPARED TO PLACEBO AT WEEK 100 AND WEEK 104 BARDOXOLONE PATIENTS WHO...
Reata Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs
November 09, 2020 06:45 ET
|
Reata Pharmaceuticals, Inc.
REPORTED POSITIVE YEAR 2 DATA FROM THE PIVOTAL CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH CHRONIC KIDNEY DISEASE CAUSED BY ALPORT SYNDROME REPORTED LONG TERM EFFICACY DATA FROM EAGLE...
Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on November 9, 2020
November 02, 2020 17:30 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will...
Reata Announces Publication of Results From Pivotal Moxie Trial of Omaveloxolone in Patients with Friedreich’s Ataxia
October 26, 2020 19:00 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that results...
Reata Pharmaceuticals, Inc. Announces Presentation of KIDNEYCODE Program at the American Society of Nephrology Kidney Week 2020 Reimagined
October 15, 2020 06:45 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (“Reata” or “the Company” or “we”) announced today the upcoming presentation of KIDNEYCODE: A Genetic Testing Program for...